Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Glucocorticoids Increase Infections, Mortality

Arthritis & Rheumatology  |  Issue: September 2024  |  August 19, 2024

Background & Objectives

Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality among patients with lupus nephritis (LN). Glucocorticoids are strongly associated with infections. The researchers aimed to assess the degree to which renal benefits outweigh the risks of infection and death.

Methods

The researchers performed a systematic review and meta-analysis of 50 control arms from 37 randomized clinical trials. The selected trials had to meet the criteria of biopsy-proven LN, use a protocolized scheme of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide, and report the outcomes of complete response, serious infections or death. The starting dose of glucocorticoids, tapering scheme and use of glucocorticoid pulses were abstracted. Meta-analysis of proportions, meta-regression and subgroup meta-analysis were performed at six and 12 months for all outcomes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results

The predicted rates of complete response, serious infections and death when starting with 25 mg of oral prednisone daily, without pulses, were 19.5%, 3.2% and 0.2%, respectively. Starting with 60 mg of oral prednisone daily, without pulses, increased the rates to 34.6%, 12.1% and 2.7%, respectively. Adding glucocorticoid pulses increased the rates of complete response and death, but not serious infections. The researchers observed a dose-response gradient between the initial glucocorticoid dose and all the outcomes at six months after accounting for the use of glucocorticoid pulses, underlying immunosuppressant and baseline proteinuria.

Conclusions

A higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, but at the cost of increased infections and mortality. Clinicians must weigh the benefits and harms that higher doses of glucocorticoids confer in the first six months of LN treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For complete details, including source material, refer to the full study.


Excerpted & Adapted From

Figueroa-Parra G, Cuéllar-Gutiérrez MC, González- Treviño M, et al. Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta-analysis of the control arms of randomized controlled trials. Arthritis Rheumatol. 2024 Sep;76(9).

Share: 

Filed under:Biologics/DMARDsConditions Tagged with:Arthritis & RheumatologyGlucocorticoidsLupus nephritismortalityRenal

Related Articles

    Immunosuppressive Treatment for Lupus in the Next Decade

    April 13, 2011

    It’s time for a new strategy

    Chronotherapy with Glucorticoids in Rheumatoid Arthritis

    January 17, 2011

    Time is of the essence in balancing risks and benefits

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences